PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2018
Filed with the SEC on Sep 12, 2018 and accepted by EDGAR at Sep 12, 2018, 17:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-05-01 to 2018-07-31 | $0 | us-gaap:Revenues |
| Research and development | 3 months2018-05-01 to 2018-07-31 | $267.8k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-05-01 to 2018-07-31 | −$1.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-05-01 to 2018-07-31 | −$1.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-05-01 to 2018-07-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2018-05-01 to 2018-07-31 | 1,046,496,430 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2018-05-01 to 2018-07-31 | −$622.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2018-07-31 | $1.8m | us-gaap:Cash |
| Current assets | At period end2018-07-31 | $2.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-07-31 | $7.1m | us-gaap:Assets |
| Current liabilities | At period end2018-07-31 | $882.9k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-07-31 | $882.9k | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-07-31 | $6.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-18-002721. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.